Publication of Annual Report and Accounts for the year ended 31 December 2024
Southampton, UK - 30 September 2025: Synairgen, the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the audited Annual Report and Accounts for the year ended 31 December 2024 have been filed with Companies House.
Synairgen has published its Annual Report and Accounts for the year ended 31 December 2024 on its website, www.synairgen.com.
Joseph Colliver
Chief Executive Officer
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.
For more information about Synairgen, please see www.synairgen.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.